History of Lysando®

2009
Lysando® AG was co-founded in 2009 in Liechtenstein by Markus Matuschka v. Greiffenclau & Dr. Stefan Miller.

2010
The following years were dedicated to the exploration of the technology. During this time, Lysando® built up enormous know-how about the technology and a huge internal biobank.

2013
During the previous years, Lysando®s researchers were able to develop numerous of customized Artilysin®s. This extended the know-how of how to design certain Artilysin®s and paved the way for Lysando®s future.

2014
Lysando® could win two licensees.

The Thailand based public company Siam Cement Group (SCG) invested in Lysando®, now holding 20% of the company.

2016
Seven years after the foundation of Lysando®, the technology platform was mature enough to finally enter the market and start licensing out the cross-industry platform technology to global leading companies. Lysando sold three additional licences in 2016.

2018
Lysando® sold four new licences.

2019
Lysando® sold five new licences. One of the new licencees is AiCuris Anti-infective Cures GmbH.

Lysando® convened an ethic committee, consisting of Leonhard Stärk (Managing Director, BRK) and Dr. Karl Liese (Senior Partner for Global Health, McKinsey & Company).

2020
Lysando® is currently executing successful clinical trials.